Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?

Kodiak Sciences Inc (NASDAQ:KOD) is among the best 52-week high US stocks to buy. On March 27, H.C. Wainwright boosted its price target on Kodiak Sciences Inc (NASDAQ:KOD) to $58 from $38 and reiterated a Buy rating on the shares. The firm raised its price target after positive Phase 3 GLOW2 trial results for tarcocimab tedromer in diabetic retinopathy.

Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?

Photo grabbed from Roivant Sciences website

On March 26, Kodiak announced positive results from a Phase 3 trial of its experimental drug called Zenkuda (tarcocimab tedromer). Zenkuda is being evaluated as a treatment for patients with diabetic ​retinopathy. This is a diabetes-related eye complication that can result in a loss of vision. The company says that around 9.7 million people in the US live with diabetic retinopathy.

In that study, 62.5% of patients treated with Zenkuda showed at least a two-step improvement in retinopathy severity. That compared with 3.3% of patients who received a sham treatment. With that, Zenkuda met the main goal of the trial.

Additionally, Zenkuda showed superiority to sham treatment in a secondary endpoint. In this case, patients who received Zenkuda treatment showed an 85% reduction in the risk of developing sight-threatening complications.

In light of these trial results, H.C. Wainwright increased its probability of success for Zenkuda in diabetic retinopathy from 35% to 70%. Moreover, the firm raised its probability of success for Zenkuda and KSI-501 in wet age-related macular degeneration from 35% to 60%.

Kodiak Sciences Inc (NASDAQ:KOD), based in Palo Alto, California, is a biopharmaceutical company focused on developing advanced therapies for retinal diseases. The company aims to improve on the existing therapies by offering next-generation medicines to help prevent blindness.

While we acknowledge the risk and potential of KOD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KOD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Must-Buy Penny Stocks to Invest In Now and 10 Best AI Stocks to Buy Under $25.

Disclosure: None. Follow Insider Monkey on Google News.